Shenzhen Salubris Pharmaceuticals (002294.SZ): XinChaoTuo, FuLiAn, and EnNaLuo Included in National Reimbursement Drug List

Stock News12-08

According to the announcement by Shenzhen Salubris Pharmaceuticals (002294.SZ), the National Healthcare Security Administration and the Ministry of Human Resources and Social Security have released the "2025 National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance" along with the "Innovative Drug List for Commercial Health Insurance."

The company's drugs XinChaoTuo (Sacubitril Valsartan Calcium Tablets) and FuLiAn® (Allisartan Indapamide Sustained-Release Tablets) have been newly added to the Class B category of the 2025 National Reimbursement Drug List through price negotiations. EnNaLuo® (Enarodustat Tablets) has successfully retained its position in the list through renewal. Additionally, XinLiTan (Allisartan Tablets) has been adjusted to the regular reimbursement drug list.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1182851781?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 17:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182851781","market":"hk","top_or_hot":-1,"title":"Shenzhen Salubris Pharmaceuticals (002294.SZ): XinChaoTuo, FuLiAn, and EnNaLuo Included in National Reimbursement Drug List","media":"Stock News","content":"<p>According to the announcement by Shenzhen Salubris Pharmaceuticals (002294.SZ), the National Healthcare Security Administration and the Ministry of Human Resources and Social Security have released the \"2025 National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance\" along with the \"Innovative Drug List for Commercial Health Insurance.\"</p>\n<p>The company's drugs XinChaoTuo (Sacubitril Valsartan Calcium Tablets) and FuLiAn® (Allisartan Indapamide Sustained-Release Tablets) have been newly added to the Class B category of the 2025 National Reimbursement Drug List through price negotiations. EnNaLuo® (Enarodustat Tablets) has successfully retained its position in the list through renewal. Additionally, XinLiTan (Allisartan Tablets) has been adjusted to the regular reimbursement drug list.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shenzhen Salubris Pharmaceuticals (002294.SZ): XinChaoTuo, FuLiAn, and EnNaLuo Included in National Reimbursement Drug List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShenzhen Salubris Pharmaceuticals (002294.SZ): XinChaoTuo, FuLiAn, and EnNaLuo Included in National Reimbursement Drug List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-08 17:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>According to the announcement by Shenzhen Salubris Pharmaceuticals (002294.SZ), the National Healthcare Security Administration and the Ministry of Human Resources and Social Security have released the \"2025 National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance\" along with the \"Innovative Drug List for Commercial Health Insurance.\"</p>\n<p>The company's drugs XinChaoTuo (Sacubitril Valsartan Calcium Tablets) and FuLiAn® (Allisartan Indapamide Sustained-Release Tablets) have been newly added to the Class B category of the 2025 National Reimbursement Drug List through price negotiations. EnNaLuo® (Enarodustat Tablets) has successfully retained its position in the list through renewal. Additionally, XinLiTan (Allisartan Tablets) has been adjusted to the regular reimbursement drug list.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"","article_id":"1182851781","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182851781","pubTimestamp":1765185263,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"According to the announcement by Shenzhen Salubris Pharmaceuticals (002294.SZ), the National Healthcare Security Administration and the Ministry of Human Resources and Social Security have released...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0028":"国家队","BK0239":"医药制造","002294":"信立泰","BK0183":"MSCI概念","BK0188":"融资融券","BK0196":"行业龙头","BK0187":"一线龙头"},"translate_title":"深圳赛百利药业（002294.SZ）：新超拓、复联、恩那罗纳入国家报销药品目录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002294":1},"content_text":"According to the announcement by Shenzhen Salubris Pharmaceuticals (002294.SZ), the National Healthcare Security Administration and the Ministry of Human Resources and Social Security have released the \"2025 National Reimbursement Drug List for Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance\" along with the \"Innovative Drug List for Commercial Health Insurance.\"\nThe company's drugs XinChaoTuo (Sacubitril Valsartan Calcium Tablets) and FuLiAn® (Allisartan Indapamide Sustained-Release Tablets) have been newly added to the Class B category of the 2025 National Reimbursement Drug List through price negotiations. EnNaLuo® (Enarodustat Tablets) has successfully retained its position in the list through renewal. Additionally, XinLiTan (Allisartan Tablets) has been adjusted to the regular reimbursement drug list.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182851781","isCrawlerRequest":true}